Jian Ge

Clinical Results of a Multicenter Study of the First-in-Human Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Hua Jiang, Baoxia Dong, Li Gao et al. · Blood · 2020 · 48 citations

Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection

Ying Wang, Yang Liu, Xu Tan et al. · Leukemia · 2020 · 47 citations

Chimeric Antigen Receptor, Viral Hepatitis, Hepatitis B Virus-infection +12

Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)phenyl)-3-(5-(<i>tert</i>-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML

Aoli Wang, Xixiang Li, Cheng Chen et al. · Journal of Medicinal Chemistry · 2017 · 37 citations · Full text

Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).

Juan Du, Weijun Fu, Hua Jiang et al. · Journal of Clinical Oncology · 2023 · 34 citations

Cell Therapy, Median Duration, Immunology +23

Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia

Cheng Zhang, Jiaping He, Li Liu et al. · Blood Cancer Journal · 2022 · 33 citations · Full text